Electromagnetic Fields: Health Effects

Debate between Tonia Antoniazzi and Seema Kennedy

Tuesday 25th June 2019 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Seema Kennedy)]

It is a pleasure to serve under your chairmanship, Mr Hollobone. I thank the hon. Member for Gower (Tonia Antoniazzi) for securing the debate and giving us the opportunity to discuss this important subject.

People are exposed to radio waves in the home, at work and throughout their daily lives. As the hon. Member for Gower mentioned, people have been talking about the issues for about 100 years, since early in the last century, but the numbers of devices and transmitters have increased rapidly, and the pace of change in how this technology becomes part of our lives can be very unsettling to some. People ask whether radio wave exposure levels are increasing and whether there could be health consequences, and I want to put on record right at the beginning that, very importantly, radio waves are non-ionising radiation. That means that the packets of energy that form the radiation are too small to break chemical bonds: the radiation cannot damage cells and cause cancer in the same way as ionising radiation. Even so, there are concerns that this type of radiation could have health effects, and a great deal of research has been done in the United Kingdom and around the world to clarify the matter, which is something the Government take very seriously.

A number of issues, both for my Department and for colleagues in others, have been raised during the debate, and I will try to address them. I will also pass them on to colleagues.

Health concerns about electromagnetic fields have been raised in relation to each successive wave of new communications services, from 2G to 3G and 4G mobile phone networks, and with wi-fi, smart meters and now 5G. I have certainly noticed the growing number of letters I have received from parliamentary colleagues, passing on their constituents’ concerns, and I am grateful for the opportunity to address some of them today.

Concerns about telecommunications networks first came to the fore in the late 1990s. A report containing an evidence review and recommendations was prepared for Government by the independent expert group on mobile phones, under the chairmanship of Sir William Stewart. A major research programme was undertaken and the international exposure guidelines were adopted, with a commitment from industry that they would be followed. Although many new services and technologies have been launched, the basic way they are delivered—by radio—has not changed, and the science of how radio waves affect the body does not change when a new technology is launched. However, the Government take people’s health concerns about electromagnetic fields very seriously. They have committed, and continue to commit, significant resources to supporting research and analysis on the topic, and policies are in place to ensure the exposure guidelines are followed.

Public Health England monitors the health-related evidence and collaborates internationally to ensure that any important new evidence is identified and responded to.

[Tonia Antoniazzi]

Will the Minister give way?

[Seema Kennedy]

The hon. Lady might be about to refer back to her speech. I was going to respond to a comment she made, but I will happily give way.

--- Later in debate ---

[Tonia Antoniazzi]

I thank the Minister for allowing me to ask this question: is she able to point out where the recent evidence that the Government and Public Health England have is? Is it in the public domain?

[Seema Kennedy]

I think the hon. Lady talked about accurate information, and about honesty concerning the information put out by Public Health England. Public Health England conducts extremely rigorous research, all based on the best available international evidence and on monitoring assessments of expert reviews. Some of those things will, of course, be in the public domain, and others will not. I will happily write to the hon. Lady with all the evidence that is available in the public domain.

The Committee on Medical Aspects of Radiation in the Environment has a watching brief on non-ionising radiation. It assesses all the available data to give health advice. Many scientific studies have been done over several decades, and a wide range of health topics have been investigated, including cancer, reproduction, cognitive effects and electrical hypersensitivity.

[Seema Kennedy]

The hon. Lady is talking about risks and hazards. [Interruption.] Yes, we are talking about two different sorts of radio wave, but she said that I would not want to go in a microwave oven. I am not suggesting that I would put myself or anyone else in a microwave oven, so we are talking about hazards and risks. The best scientific evidence given to Government is that the radiation is safe, and I was going to go on to talk about the evidence that Government have used before addressing some of the points that the hon. Member for Gower raised. I apologise if I have not quite understood the point made by the hon. Member for Glasgow North West (Carol Monaghan); I will happily discuss it with her later.

Expert groups in the UK and around the world have examined the evidence and published many comprehensive reports. In the UK, the Advisory Group on Non-ionising Radiation produced reports in 2003 and 2012. The Government have played their role in the international effort to learn more about the health effects of radio- wave exposure. They supported the dedicated mobile telecommunications and health research programme that ran from 2001 to 2012 and they continue to fund research.

A challenge in understanding the evidence is that some studies report effects, while others do not. Sophisticated analyses are needed to draw studies together, considering their strengths and weaknesses and working out what they mean collectively, which is the role of expert groups. Simply counting or listing studies that have found effects is not an adequate way of assessing where the overall evidence lies.

An expert group reporting to the European Commission delivered a review in 2015, and the World Health Organisation is currently carrying out a major review on radio waves and health, which will include studies performed over the past 25 years. Overall, those expert groups have not found any clear evidence of adverse health effects occurring if the International Commission on Non-Ionizing Radiation Protection exposure guidelines are followed. The ICNIRP exposure restrictions have been incorporated into a 1999 European Council recommendation on limiting public exposures to electromagnetic fields. The United Kingdom and Public Health England support that recommendation.

Since 1996, the World Health Organisation has been running an international electromagnetic field project that provides a forum for countries to gather together, discuss and share knowledge on this topic. The WHO’s main conclusion is that electromagnetic field exposures below the limits recommended in the International Commission on Non-Ionizing Radiation Protection guidelines do not appear to have any known consequence for health. However, as the hon. Member for Gower and other Members have mentioned, that does not mean that people who have electrical hypersensitivity do not have symptoms. Those symptoms are real and can be very debilitating, and the Department’s guidance is that those people should seek medical advice, so that their personal situation can be taken into account and the best possible treatments found.

I will also address the points raised by many hon. Members about the effects of screen time on the mental health of children; as any parent can attest, there are some effects. The shadow Minister, the hon. Member for Washington and Sunderland West (Mrs Hodgson), referred to SCAMP, and the Government conduct research that looks at the effects of technologies on schoolchildren.

Exposure levels reduce very rapidly with increasing distance from transmitting antennae, which means that being in immediate proximity to the transmitting antenna of a mobile phone handset held next to the head is different from living near a base station. There is long-standing precautionary advice from Public Health England and the NHS for mobile phone users, and research is continuing. We are continually looking at the evidence and updating our advice.

[Tonia Antoniazzi]

What work has been undertaken by Public Health England to look for evidence of risk in mobile phone usage? Is it looking at what damage it is actually doing, rather than saying, “Well, it is not really hurting anybody”?

[Seema Kennedy]

Public Health England takes its role very seriously, and is always monitoring the evidence. Since perhaps 10 years ago, there has been a lot of research into having mobile phones next to one’s ear. Of course, the way we use our phones is changing, but Public Health England is always looking at this issue and reviewing the best available evidence.

There has been a general trend from 2G through to 5G for transmitters to become smaller, to be mounted nearer to the ground, and to use less transmitted power. The hon. Member for Stroud (Dr Drew) raised a point about the electronic communications code, which I think is a matter for colleagues in the Ministry of Housing, Communities and Local Government. The hon. Member for Swansea West (Geraint Davies) has left, but I do not think we are cutting down trees; in fact, I am sure that the Government have committed to planting more trees. I know that the Secretary of State is very keen on them, so I will write to him on that issue.

To answer the questions that were asked about radio frequency fields and cancer, a working group of the International Agency for Research on Cancer reviewed the health effects of exposure to RF fields and concluded that such exposures are possibly carcinogenic to humans—group 2B, based on IARC’s classification scheme. There was a minority opinion in the working group that current evidence for humans was inadequate, and therefore there was no conclusion about a causal association. In terms of the different classes of carcinogens, there is a statement on the PHE website that responds to the IARC classification. PHE has summary advice statements that it sends to inquirers with a full explanation of different carcinogens; there is a broad spectrum, including petrol engine exhausts, bracken fern and talc-based body powder.

Since 2001, the Office of Communications has been carrying out an audit of the emissions from mobile phone base stations. The Advisory Group on Non-Ionising Radiation’s 2012 report contained a summary of over 3,000 measurements made at over 500 sites by Ofcom. The maximum exposure found at any location was hundreds of times below the international guideline levels, and typical exposures were much lower still. Public Health England advises that there may be a small increase in overall exposure to radio waves when 5G is added to an existing network or a new area, but that is expected to remain low relative to guidelines.

I hope I have demonstrated that the Government take seriously the potential health effects of the introduction of 5G, and that Public Health England is well placed to identify and respond to any important new evidence that may emerge. I reiterate that the public’s levels of exposure to electromagnetic fields from telecommunications networks are currently very low in relation to the international guideline levels, and are expected to stay that way after the deployment of 5G.

Medical Cannabis under Prescription

Debate between Tonia Antoniazzi and Seema Kennedy

Monday 20th May 2019 Commons Chamber

[Seema Kennedy]

Of course I could as a parent, but again, I am not a doctor, and I am not here to make that call. What I would say is that I am very happy to meet the hon. Gentleman to get more of the facts he is presenting to me.

What is needed to support such prescription is evidence of efficacy, and for public funding evidence of cost-efficacy. That is the system we apply to all medicines and medical devices in the UK, and cannabis should not be treated any differently. The current evidence base has been summarised by the professional bodies in their interim clinical guidance, and it will be further examined and reported on by NICE shortly.

[Tonia Antoniazzi]

I have one question for the Minister: has the cost analysis been done on a particular case? When I spoke earlier, I spoke about Alfie Dingley. It would be very interesting to see the impact of his case financially–the benefit that has been gained to the NHS and the money that it has saved the NHS since he has been taking the drug.

[Seema Kennedy]

I apologise to the hon. Lady, because she did ask me that, and I am afraid I forgot to send a note to the Box. I am happy to write to her about whether that analysis has been done.

Many hon. Members, including my hon. Friend the Member for South Suffolk, talked about funding. Funding decisions are local decisions with clear local procedures. The process review is looking at this, and as I have said, it will report shortly. I call on the industry to invest in more trials, and to publish the results and the full underpinning data, because we all want to see licensed products that doctors can use with confidence.

Where there is supporting evidence, the Government and the NHS will work with companies to make the products available. Indeed, more than 110 patients are now being treated with a pure CBD extract product—Epidiolex, which numerous hon. Members have referred to—on an early access programme, ahead of a licensing decision by the European Medicines Agency. In developing a licensed product, the evidence has been generated on the safety profile and effectiveness of the product. It is this that provides clinicians with the confidence to prescribe and the system with the evidence it needs to make decisions on routine funding. The NHS does not routinely fund any new medicine until it has been through a process of evaluation to ensure that it is safe, effective and represents value for money.

On another point that the hon. Member for Gower brought up, about one of her constituents going on the Epidiolex trial, the specialist centres around the country are referring patients to GW Pharmaceuticals. There are certain criteria and a certain number of places, but if she wrote to me, I would be happy to meet her and we could discuss that further.

We need to develop further our knowledge base on these products. That is why good-quality clinical trials are imperative. We need to know more about the scale of the benefit of cannabis-based products across a wide range of indications. We also need to understand how this compares with existing treatments and, indeed, other promising new drugs that may be as effective.